Cottage Center for Orthopedics Helps Gary Enjoy an Active Life Again

(44)

Dr. Hurvitz on Treatment Hypotheses for TNBC

(2:)

Dr. Hurvitz on Pembrolizumab for TNBC

(1:36)

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

(58)

Dr. Hurvitz on How to Navigate HER2-Targeted Therapy in Breast Cancer

(1:37)

Dr. Hurvitz on the Impact of Biosimilars

(1:38)

Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer

(2:1econd)

Dr. Hurvitz on neoMONARCH Trial for HR+ Breast Cancer

(2:)

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

(1:3)

Anti-HER2 Mechanisms of Approved HER2 Inhibitors

(5:5)

SickKids $50 Million Gift Announcement

(52:31)

Biosimilars and Biologics

(38:15)

m4 Award 23 for Prof. Ulrike Protzer \u0026 team TherVacB for therapeutic vaccination against hepatitis B

(2:42)

Robotic heart surgery, heart valve disorders, and coronary arteries: Expert Q\u0026A

(27:13)

Dr. Eric C. Leuthardt Installation Video

(1:7:54)

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance

(51:40)

Interview with Prof. Dr. Ulrike Protzer, International HBV Meeting

(10:18)

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches

(30:10)

Dr. Hurvitz on the Clinical Use of Biosimilars in Oncology

(58)

Dr. Hurvitz on Reducing Potential Exposure to COVID-19

(1:35)

Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

(1:29)

Dr. Hurvitz on Biosimilars in Breast Cancer

(1:46)

Dr. Hurvitz on the Future of the Treatment of TNBC

(2:16)

Dr. Hurvitz on Patient Outcomes and PIK3CA Mutations

(1:59)

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

(1:39)

Dr. Hurvitz on the FDA Approval Process for Biosimilars

(1:55)

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

(1:41)

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

(1:20)

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

(1:26)